Pfizer Targets Pediatric Ulcerative Colitis With New Etrasimod Trial: What Investors Should Watch

robot
摘要生成中

Pfizer Inc. is initiating a Phase 2 trial for its drug etrasimod in children with moderate to severe ulcerative colitis, aiming to evaluate its efficacy and safety in this young patient population. The open-label, single-arm study will have participants treated for up to 52 weeks with an option for a long-term extension. This move expands etrasimod’s potential market and positions Pfizer against competitors like AbbVie and Johnson & Johnson in the inflammatory bowel disease space.

此页面可能包含第三方内容,仅供参考(非陈述/保证),不应被视为 Gate 认可其观点表述,也不得被视为财务或专业建议。详见声明
  • 赞赏
  • 评论
  • 转发
  • 分享
评论
请输入评论内容
请输入评论内容
暂无评论